share_log

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/11/22 19:06

Moomoo AI 已提取核心信息

Addex Therapeutics reported financial results for Q3 2024, with a net profit of CHF 8.3 million for the nine months ended September 30, 2024, primarily driven by the Neurosterix Transaction completed in April 2024. The transaction generated proceeds of CHF 5.0 million in cash and a 20% equity stake in Neurosterix valued at CHF 9.4 million.Revenue from continuing operations decreased to CHF 0.4 million for the nine months, compared to CHF 1.5 million in the same period of 2023. Operating costs from continuing operations reduced to CHF 2.7 million from CHF 3.0 million, mainly due to lower external R&D costs and D&O insurance expenses. Cash and cash equivalents stood at CHF 3.3 million as of September 30, 2024.The company retained its partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant for Parkinson's disease and post-stroke recovery. In August 2024, Indivior selected a compound for substance use disorder development, while Addex retained rights to develop a GABAB PAM program for chronic cough.
Addex Therapeutics reported financial results for Q3 2024, with a net profit of CHF 8.3 million for the nine months ended September 30, 2024, primarily driven by the Neurosterix Transaction completed in April 2024. The transaction generated proceeds of CHF 5.0 million in cash and a 20% equity stake in Neurosterix valued at CHF 9.4 million.Revenue from continuing operations decreased to CHF 0.4 million for the nine months, compared to CHF 1.5 million in the same period of 2023. Operating costs from continuing operations reduced to CHF 2.7 million from CHF 3.0 million, mainly due to lower external R&D costs and D&O insurance expenses. Cash and cash equivalents stood at CHF 3.3 million as of September 30, 2024.The company retained its partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant for Parkinson's disease and post-stroke recovery. In August 2024, Indivior selected a compound for substance use disorder development, while Addex retained rights to develop a GABAB PAM program for chronic cough.
Addex Therapeutics公布了2024年第三季度的财务结果，截至2024年9月30日的九个月内净利润为830万瑞士法郎，主要得益于2024年4月完成的Neurosterix交易。该交易产生了500万瑞士法郎的现金收入，以及在Neurosterix中持有20%股权，估值为940万瑞士法郎。持续经营的营业收入为40万瑞士法郎，较2023年同期的150万瑞士法郎有所下降。持续经营的运营成本从300万瑞士法郎减少至270万瑞士法郎，主要由于外部研发成本和D&O保险费用的降低。截至2024年9月30日，现金及现金等价物为330万瑞士法郎。公司与强生和Indivior保持合作关系，拥有包括用于治疗帕金森病和中风后恢复的dipraglurant在内的临床阶段资产。2024年8月，Indivior选择了一种用于物质使用障碍开发的Compound，而Addex保留了开发用于慢性咳嗽的GABAb PAm项目的权利。
Addex Therapeutics公布了2024年第三季度的财务结果，截至2024年9月30日的九个月内净利润为830万瑞士法郎，主要得益于2024年4月完成的Neurosterix交易。该交易产生了500万瑞士法郎的现金收入，以及在Neurosterix中持有20%股权，估值为940万瑞士法郎。持续经营的营业收入为40万瑞士法郎，较2023年同期的150万瑞士法郎有所下降。持续经营的运营成本从300万瑞士法郎减少至270万瑞士法郎，主要由于外部研发成本和D&O保险费用的降低。截至2024年9月30日，现金及现金等价物为330万瑞士法郎。公司与强生和Indivior保持合作关系，拥有包括用于治疗帕金森病和中风后恢复的dipraglurant在内的临床阶段资产。2024年8月，Indivior选择了一种用于物质使用障碍开发的Compound，而Addex保留了开发用于慢性咳嗽的GABAb PAm项目的权利。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Dogwood Therapeutics
    DWTX
    -- 13.350
    Transcode Therapeutics
    RNAZ
    -- 5.500
    Evaxion Biotech
    EVAX
    -- 3.640
    Hepion Pharmaceuticals
    HEPA
    -- 0.2000
    Nutriband
    NTRB
    -- 9.900
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球股市新风口在哪里？
    ▪️加密货币政策能否利好crypto？ ▪️关税政策能否利好中概等海外资产？ ▪️在特朗普政策下，有哪些投资机会值得关注？ 展开
    离川普上台只有7天了～
    热门中概股
    追踪最热门的中概股实时资讯。